|
|
||||||||
CLINICAL STUDIES |
Department of Public Health, Norwegian University of Science and Technology, NO-7489 Trondheim, Norway1 Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark2 Department of Microbiology, Ullevål University Hospital, Oslo, Norway3 Department of Microbiology, Asker and Bærum Hospital, Bærum, Norway4 Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway and 5 Department of Obstetrics and Gynecology and Faculty of Medicine, Akershus University Hospital, University of Oslo, Lørenskog, Norway
(Correspondence should be addressed to L J Vatten; Email: lars.vatten{at}ntnu.no)
Objective: To assess whether circulating IGF-I and IGF-binding protein-1 (IGFBP-1) in the first and second trimester are associated with subsequent risk of preterm and term preeclampsia.
Methods: Nested case–control study within a cohort of 29 948 pregnant women. Cases were women, who later developed preeclampsia, and controls were randomly selected women, who did not develop preeclampsia. IGF-I and IGFBP-1 were measured with ELISA in maternal blood samples that were collected in the first and second trimesters. We assessed associations of IGF-I and IGFBP-1 concentrations with later development of preterm (before the 37th week of gestation) and term preeclampsia.
Results: An increase in IGF-I from the first to second trimester was associated with higher risk of preterm preeclampsia; the odds ratio (OR) for the highest compared with lowest quartile of increase was 4.9 (95% confidence interval, 1.1–21.8). Low concentrations of IGFBP-1, both in the first and in the second trimesters, were related to higher risk of term preeclampsia (OR 4.0, 95% confidence interval, 1.9–8.4) and moderately increased risk of preterm preeclampsia (OR 2.3, 95% confidence interval, 1.2–4.4).
Conclusion: The higher risk of preterm preeclampsia related to IGF-I increase may reflect placental disease, whereas low concentrations of IGFBP-1 associated with term preeclampsia may reflect maternal metabolic aberrations, indicating different etiologies in preeclampsia.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |